

FAX (617) 742-4214 lc@lahive.com

JOHN A. LAHIVE, JR. (1928-1997) THOMAS V. SMURZYNSKI RALPH A. LOREN GIULIO A. DeCONTI, JR. ANN LAMPORT HAMMITTE FLIZABETH A. HANLEY AMY BAKER MANDRAGOURAS ANTHONY A. LAURENTANO KEVIN J. CANNING JANE E. REMILLARD Deann FORAN SMITH PETER C. LAURO JEANNE M. DIGIORGIO DEBRA J. MILASINCIC, Ph.D. DAVID J. RIKKERS DAVID R. BURNS JOHN S. CURRAN SEAN D. DETWEILER

CYNTHIA L. KANIK, PI MEGAN E. WILLIAMS, Ph.D. RICHA NAND MICHAEL PHILLIPPS LISA M. DIROCCO HATHAWAY P RUSSELL \*\* MARIA LACCOTRIPE ZACHARAKIS, Ph.D. VINCENT P. LOCCISANO MERIDETH C. ARNOLD

SENIOR COUNSEL JAMES E. COCKFIELD

OF COUNSEL JEREMIAH LYNCH WILLIAM A. SCOFIELD, JP SIBLEY P. REPPERT

PATENT AGENTS THEODORER WEST SHAYNE Y, HUFF, Ph.D. DANIEL B. KO

TECHNICAL SPECIALIST CYNTHIA M. SOROOS PETER W. DINI, Ph.D. **EUIHOON LEE** CATHERINE E. McPHERSON ERIC F. WAGNER, Ph.D. JACOB G. WEINTRAUB JONATHAN M. SPARKS, Ph D. CRISTIN E. HOWLEY, Ph.D.

Admitted in NY only

## RECEIVED

OCT 2 4 2002

TECH CENTER 1600/2900

Commissioner for Patents Washington, D.C. 20231

Re: U.S. Patent Application No.: 09/777317

For: Tetracycline-Regulated Transcriptional Activator Fusion Proteins:

Priord Hermann et al.

October 8, 2002

Filed: February 5, 2001

Our Ref. No.: BBI-013C3CN3

Dear Sir:

I enclose herewith for filing in the above-identified application the following:

- Information Disclosure Statement: 1.
- 2. PTO Form 1449; and
- 3. A Return Postcard.

No additional costs are believed to be due in connection with the filing of this Information Disclosure Statement. However, please charge any necessary fees in connection with the enclosed statement to our Deposit Order Account No. 12-0080. For this purpose, a duplicate of this sheet is attached.

I hereby certify that this correspondence is deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, Washington, D.C. 20231 on:

Giulio A. De Conti, Jr., Esq., Registration No

Respectfully submitted,

LAHIVE & COCKFIELD, LLP

Giulio A. DeConti, Jr., Esq. Registration No. 31,503

Attorney for Applicants

TECH CENTER 1600/290







## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Group Art Unit: 1775

Examiner: Shukla, R.

RECEIVEL OCT 21 2002 C 1700 MAIL ROO

In re the application of: Bujard, Hermann et al.

Serial No.: 09/777317

Filed: February 5, 2001

For: Tetracycline-Regulated Transcriptional Activator

Fusion Proteins

Attorney Docket No.: BBI-013C3CN3

Commissioner for Patents Washington, D.C. 20231

Certificate of First Class Mailing (37 CFR 1.8(a))

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, Washington, D.C. 20231 on the date set forth below.

**October 8, 2002** 

Date of Signature and of Mail Deposit

Giulio A. DeConti, Jr., Esq.

Registration No. 31,503 Attorney for Applicants

## INFORMATION DISCLOSURE STATEMENT

Dear Sir:

Applicants and their Attorney are aware of the following patents, publications or other information, which are cited on the attached PTO Form 1449, and in accordance with 37 CFR §1.97 hereby submit these forms for the Examiner's consideration.

The present application is a Continuation Application of U.S. Serial No. 09/163276, filed September 29, 1998 (Atty. Docket No. BBI-013C3CN), which is a Continuation Application of U.S.P.N. 5,888,981, issued March 30, 1999 (Atty. Docket

No. BBI-013CP3), which is a Continuation-in-Part Application of U.S.P.N. 5,650,298 issued July 22, 1997 (Atty. Docket No. BBI-013). All references listed on the enclosed PTO Form 1449 have been previously cited by or submitted to the Office in the prior applications, and, in accordance with 37 CFR §1.98(d), copies of these references are not enclosed herewith, but will be provided upon request.

This statement is not to be interpreted as a representation that the cited publications are material, that an exhaustive search has been conducted, or that no other relevant information exists. Nor shall the citation of any publication herein be construed *per se* as a representation that such publication is prior art. Moreover, Applicants understand that the Examiner will make an independent evaluation of the cited publications.

Under 37 CFR § 1.97(b)(3), no additional costs are believed to be due in connection with the filing of this disclosure. If, however, a first Office Action on the merits issues in this application bearing a mailing date prior to the date of this Information Disclosure Statement, please charge the appropriate fee as required under 37 CFR §1.17(p) to our Deposit Order Account No. 12-0080.

Respectfully submitted,

LAHIVE & COCKFIELD, LLP

Giulio A. DeConti, Jr., Esg

Registration No. 31,503

Attorney for Applicants (

28 State Street Boston, MA 02109 (617) 227-7400

Date: October 8, 2002

GAD/CEH/alf